CEOs of The LYCRA Company & Qore join Global Fashion Summit lineup
The LYCRA Company, a global leader in developing sustainable fibers and solutions for the apparel industry, announced that its CEO, Gary Smith, is a speaker at the Global Fashion Summit: Copenhagen Edition 2025. He will be joined on stage by Jon Veldhouse, CEO of Qore, the maker of QIRA, a next-generation BDO and a key ingredient in bio-derived LYCRA fiber, which is launching later this year.
The LYCRA Company and Qore will debut at the Global Fashion Summit 2025 in Copenhagen, with CEOs Gary Smith and Jon Veldhouse discussing their new bio-derived LYCRA fibre made with QIRA. Launching later this year, the fibre uses corn-based BDO, offers 70 per cent renewable content, and can cut LYCRA's carbon footprint by up to 44 per cent, requiring no fabric or process changes.
Smith and Veldhouse will discuss the development of this sustainable fiber made from annually renewable field corn during their Fireside Chat: From Farm to Fashion. Their session takes place on Wednesday, June 4, at 3:35 CEST in the DR Concert Hall. The discussion will be moderated by Amy Nguyen, a researcher, writer, and founder of Sustainable & Social.
This is the first time both companies are participating in the Global Fashion Summit, a premier platform focused on sustainability in the fashion industry. The companies have a prominent exhibit space for attendees to learn more about bio-derived LYCRA fiber made with QIRA. Here, visitors can be transported to the Qore site and cornfields in Iowa through a virtual reality experience.
Bio-derived LYCRA EcoMade fiber will be the world's first large-scale, commercially available renewable elastane. It delivers equivalent performance to the original LYCRA fiber and serves as a one-to-one replacement with no re-engineering of fabrics, processes, or garment patterns required. The product contains 70 percent renewable content and can potentially reduce the carbon footprint of LYCRA fiber by up to 44 percent. The LYCRA Company holds patents related to this renewable fiber in several regions including Europe.
'We're proud to join the Global Fashion Summit for the first time and showcase how collaboration can accelerate a more sustainable future for fashion,' said Gary Smith, CEO of The LYCRA Company. 'Partnering with Qore has enabled us to scale innovation that is renewable and ready to meet the demands of global fashion brands striving to meet their sustainability goals.'
The newly constructed Qore site in Eddyville, Iowa, began operating last month and has started producing QIRA. The company will host a grand opening celebration in July.
'Starting production at our new state-of-the-art facility marks a major step forward—not just for Qore, but for the entire industry,' said Jon Veldhouse, CEO of Qore. 'With QIRA now being made in Iowa from annually renewable field corn, we're turning sustainable innovation into reality and helping our partners bring next-generation materials to market.' Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.
Fibre2Fashion News Desk (HU)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
21 hours ago
- Business Standard
Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda
Global biotech major Alvotech and Hyderabad-based Dr Reddy's Laboratories (DRL) have entered into a collaboration to co-develop, manufacture, and commercialise a biosimilar version of Merck's blockbuster cancer drug Keytruda (pembrolizumab), which recorded global sales of $29.5 billion in 2024. Shares of DRL rose 3 per cent on Thursday on the BSE following the announcement. Under the agreement, both parties will jointly manage development and manufacturing responsibilities, while sharing associated costs. Each company will also hold global commercialisation rights, subject to certain exceptions. Keytruda, developed by Merck & Co., is used to treat a wide range of cancers, including lung, melanoma, and head and neck cancers. With patents for Keytruda expected to expire in major markets over the next few years, competition among biosimilar developers is intensifying. The partnership is a strategic boost to Dr Reddy's oncology portfolio—a key therapeutic area for the company—and significantly expands Iceland-based Alvotech's biosimilar pipeline. The tie-up comes amid growing global demand for cost-effective biologic alternatives in cancer care, especially in immuno-oncology, where Keytruda remains a dominant therapy. 'We are happy to collaborate with Alvotech for the pembrolizumab biosimilar,' said Erez Israeli, CEO of Dr Reddy's. 'Oncology has been a top focus therapy area for us, and this collaboration further enhances our capabilities.' Alvotech Chairman and CEO Róbert Wessman said the partnership would accelerate development while broadening global access to critical biologics. 'This agreement demonstrates our ability to leverage our R&D and manufacturing platform to pursue growing global markets,' he said. Alvotech, listed on Nasdaq, is focused solely on biosimilars and already has approvals for adalimumab and ustekinumab biosimilars. Its pipeline includes candidates for autoimmune, respiratory, and oncologic indications. Dr Reddy's, which has commercialised six biosimilars in India and over 30 countries, has been scaling up global biologics operations. It launched its first biosimilar in the UK—Versavo (bevacizumab)—in 2024, and pegfilgrastim in the US and Europe through partners. With this collaboration, both companies aim to play a larger role in shaping the next phase of affordable cancer care globally.
Fibre2Fashion
a day ago
- Fibre2Fashion
Haelixa CEO Patrick Strumpf to speak at Global Fashion Summit 2025
Haelixa is proud to announce that our CEO, Patrick Strumpf, will be speaking on a high-profile panel at the upcoming Global Fashion Summit 2025 taking place in Copenhagen from June 3–5. The summit, organized by Global Fashion Agenda, gathering thought leaders and changemakers from across the fashion and textile industry. Haelixa CEO Patrick Strumpf will speak at the Global Fashion Summit 2025 in Copenhagen on June 4. He'll join the 'Fibre Futures' panel to discuss next-gen materials, traceability, and innovation in fashion. Strumpf will highlight Haelixa's DNA-powered solutions and the need for transparency to scale sustainable and circular supply chains industry-wide. Patrick Strumpf will join the panel discussion titled 'Fibre Futures', which will discuss the critical role of next-generation materials in transforming the fashion supply chain. With the industry increasingly shifting towards sustainability and circularity, this conversation will highlight the challenges and opportunities of scaling fibre innovations that reduce environmental impact and drive systemic change. The panel will bring together experts in fibre development, recycling technologies, and regenerative systems to discuss how innovation, policy, and investment must align to make circular models commercially viable and environmentally sound. Patrick will discuss the urgent need for transparency and traceability in the fashion supply chain – an area where Haelixa continues to lead with cutting-edge traceability solutions using DNA technology. His participation reflects our ongoing commitment to fostering a more responsible and accountable fashion industry. 'We're building bridges of trust between all supply chain partners. Our DNA-powered traceability solution creates visibility from fibre to finished garment.' Patrick Strumpf, CEO Haelixa Panel Details 'Fibre Futures' Patrick will speak on June 4th from 11:30 AM to 12:35 PM in a dynamic panel session focused on pioneering technologies and material innovation. This forward-looking discussion will explore: Pioneering technologies are redefining material innovation, transforming nature, waste and beyond into boundary-breaking fabrics From a product point of view, what are the barriers and bridges on the pathway to scaling textile and material innovation? What cutting-edge strategies and technologies can drive fibre-to-fibre by incentivising new materials, given resource capacity and demand? Joining Patrick on stage will be fellow thought leaders and innovators from across the textile innovation ecosystem, each contributing unique perspectives on scaling sustainable solutions and transforming the future of materials: Brooke Roberts-Islam Writer, Author & Consultant, Forbes, Business of Fashion, Penguin & Techstyler Andreas Dorner General Manager, RE&UP Nienke Steen Global Director for Apparel, Textiles and Footwear, Cradle to Cradle Products Innovation Institute Tana Dai General Manager, Erdos Cashmere Group Thamires Pontes CEO & Founder, Phycolabs Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Fibre2Fashion News Desk (HU)
The Hindu
a day ago
- The Hindu
Dr. Reddy's, Alvotech to co-develop, market biosimilar of Merck's cancer drug Keytruda
Pharma major Dr. Reddy's Laboratories and Nasdaq-listed global biotech firm Alvotech will co-develop, manufacture and commercialise a biosimilar candidate to Merck's cancer drug Keytruda (pembrolizumab) for global markets. They will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs as well as the responsibilities. 'Subject to certain exceptions, each party will have the right to commercialise the product globally,' Dr. Reddy's and Alvotech said on Thursday (June 5, 2025) in a joint statement announcing the signing of a licence agreement. The collaboration will combine their proven capabilities in biosimilars thus speeding up the development process and extending global reach for the biosimilar candidate. A registered trademark of Merck Sharp & Dohme Corp, Keytruda is indicated for the treatment of numerous cancer types. In 2024, the worldwide sales of Keytruda were $29.5 billion. Oncology top focus therapy 'Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' Dr. Reddy's CEO Erez Israeli said. Alvotech chairman and CEO Robert Wessman said 'we are pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets.'
